Troriluzole in Adult Subjects With Spinocerebellar Ataxia
Status:
Active, not recruiting
Trial end date:
2024-01-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus
placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).